Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone methyl in ADPKD
NCT03918447Phase 3Terminated
- Sponsor
- Biogen
- Start
- May 2019
- Primary completion
- Aug 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of bardoxolone methyl in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Biogen. Started May 2019; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03918447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918447.